Soleno Therapeutics stock drops on FAERS update, Baird maintains Outperform rating

Soleno Therapeutics (SLNO) saw a stock selloff after an FDA database report linked a patient death by pulmonary embolism to its Vykat XR treatment. However, the company clarified the physician deemed the event unrelated to the drug, citing patient comorbidities. Consequently, multiple analysts, including Baird, TD Cowen, Piper Sandler, Wells Fargo, and Cantor Fitzgerald, have reiterated or initiated positive ratings (Outperform/Buy/Overweight) and maintained high price targets ($120-$145), viewing the market reaction as 'overdone' and an attractive buying opportunity given strong prescription numbers and launch trajectory.

Analysis

Soleno Therapeutics (SLNO) experienced a significant stock selloff following an update to the FDA Adverse Event Reporting System (FAERS) database, which included a patient death due to pulmonary embolism. However, the market's reaction appears disconnected from the clinical context and subsequent analyst commentary. According to Soleno's 8-K filing, the reporting physician assessed the event as unrelated to the company's drug, Vykat XR, pointing to the patient's comorbidities—lymphedema, superficial thrombophlebitis, and obesity—as significant baseline risk factors. This view is overwhelmingly supported by a strong consensus of investment banks. Baird characterized the selloff as "far overdone" and an "attractive opportunity," reiterating an Outperform rating and a $121 price target. This bullish sentiment is echoed by TD Cowen ($120 PT), Wells Fargo ($123 PT), and Cantor Fitzgerald ($123 PT), all holding Buy or Overweight ratings. Furthermore, Piper Sandler maintained its Overweight rating with a high-end target of $145, citing fundamental strengths such as strong prescription numbers and insurance coverage that support a positive launch trajectory for Vykat XR.

Key Decisions for Investors

• Given the broad analyst consensus that the stock's selloff was an overreaction, investors could view the current valuation as a compelling entry point, capitalizing on a perceived mispricing of headline risk.
• Investors should monitor the commercial launch metrics for Vykat XR, specifically prescription volume and insurance reimbursement rates, as these are the key fundamental drivers cited by analysts underpinning the bullish thesis.
• While the physician's assessment is reassuring, the primary risk remains regulatory perception; therefore, any future communications from the FDA or patterns in the FAERS database concerning Vykat XR must be watched closely as they could rapidly alter the investment case.